Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis

NCT05232825 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT05232825
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05232825 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Completed
Start date
May 3, 2022
Completion date
June 6, 2025
Enrollment
236 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

primary progressive multiple sclerosis, relapsing multiple sclerosis